Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Standard

Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. / Hansen, J E; Clausen, H; Nielsen, C; Teglbjaerg, L S; Hansen, L L; Nielsen, C M; Dabelsteen, E; Mathiesen, Lars Reinhardt; Hakomori, S I; Nielsen, Jens Ole.

I: Journal of Virology, Bind 64, Nr. 6, 1990, s. 2833-2840.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Harvard

Hansen, JE, Clausen, H, Nielsen, C, Teglbjaerg, LS, Hansen, LL, Nielsen, CM, Dabelsteen, E, Mathiesen, LR, Hakomori, SI & Nielsen, JO 1990, 'Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.', Journal of Virology, bind 64, nr. 6, s. 2833-2840. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1692349&query_hl=6>

APA

Hansen, J. E., Clausen, H., Nielsen, C., Teglbjaerg, L. S., Hansen, L. L., Nielsen, C. M., Dabelsteen, E., Mathiesen, L. R., Hakomori, S. I., & Nielsen, J. O. (1990). Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. Journal of Virology, 64(6), 2833-2840. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1692349&query_hl=6

Vancouver

Hansen JE, Clausen H, Nielsen C, Teglbjaerg LS, Hansen LL, Nielsen CM o.a. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. Journal of Virology. 1990;64(6):2833-2840.

Author

Hansen, J E ; Clausen, H ; Nielsen, C ; Teglbjaerg, L S ; Hansen, L L ; Nielsen, C M ; Dabelsteen, E ; Mathiesen, Lars Reinhardt ; Hakomori, S I ; Nielsen, Jens Ole. / Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. I: Journal of Virology. 1990 ; Bind 64, Nr. 6. s. 2833-2840.

Bibtex

@article{0fab82bb5a0d4b13a48d86e1ebcd06ef,
title = "Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.",
abstract = "Carbohydrate structures are often involved in the initial adhesion of pathogens to target cells. In the present study, a panel of anticarbohydrate monoclonal antibodies (MAbs) was tested for their ability to inhibit in vitro human immunodeficiency virus infectivity. MAbs against three different N- and O-linked carbohydrate epitopes (LeY, A1, and sialyl-Tn) were able to block infection by cell-free virus as well as inhibit syncytium formation. Inhibition of virus infectivity was independent of virus strain (HTLVIIIB or patient isolate SSI-002), the cell line used for virus propagation (H9 or MT4), and the cell type used as the infection target (MT4, PMC, or selected T4 lymphocytes). Inhibition was observed when viruses were preincubated with MAbs but not when cells were preincubated with MAbs before inoculation, and the MAbs were shown to precipitate 125I-labeled gp120. The MAbs therefore define carbohydrate structures expressed by the viral envelope glycoprotein gp120, indicating that glycans of the viral envelope are possible targets for immunotherapy or vaccine development or both.",
author = "Hansen, {J E} and H Clausen and C Nielsen and Teglbjaerg, {L S} and Hansen, {L L} and Nielsen, {C M} and E Dabelsteen and Mathiesen, {Lars Reinhardt} and Hakomori, {S I} and Nielsen, {Jens Ole}",
year = "1990",
language = "English",
volume = "64",
pages = "2833--2840",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "6",

}

RIS

TY - JOUR

T1 - Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

AU - Hansen, J E

AU - Clausen, H

AU - Nielsen, C

AU - Teglbjaerg, L S

AU - Hansen, L L

AU - Nielsen, C M

AU - Dabelsteen, E

AU - Mathiesen, Lars Reinhardt

AU - Hakomori, S I

AU - Nielsen, Jens Ole

PY - 1990

Y1 - 1990

N2 - Carbohydrate structures are often involved in the initial adhesion of pathogens to target cells. In the present study, a panel of anticarbohydrate monoclonal antibodies (MAbs) was tested for their ability to inhibit in vitro human immunodeficiency virus infectivity. MAbs against three different N- and O-linked carbohydrate epitopes (LeY, A1, and sialyl-Tn) were able to block infection by cell-free virus as well as inhibit syncytium formation. Inhibition of virus infectivity was independent of virus strain (HTLVIIIB or patient isolate SSI-002), the cell line used for virus propagation (H9 or MT4), and the cell type used as the infection target (MT4, PMC, or selected T4 lymphocytes). Inhibition was observed when viruses were preincubated with MAbs but not when cells were preincubated with MAbs before inoculation, and the MAbs were shown to precipitate 125I-labeled gp120. The MAbs therefore define carbohydrate structures expressed by the viral envelope glycoprotein gp120, indicating that glycans of the viral envelope are possible targets for immunotherapy or vaccine development or both.

AB - Carbohydrate structures are often involved in the initial adhesion of pathogens to target cells. In the present study, a panel of anticarbohydrate monoclonal antibodies (MAbs) was tested for their ability to inhibit in vitro human immunodeficiency virus infectivity. MAbs against three different N- and O-linked carbohydrate epitopes (LeY, A1, and sialyl-Tn) were able to block infection by cell-free virus as well as inhibit syncytium formation. Inhibition of virus infectivity was independent of virus strain (HTLVIIIB or patient isolate SSI-002), the cell line used for virus propagation (H9 or MT4), and the cell type used as the infection target (MT4, PMC, or selected T4 lymphocytes). Inhibition was observed when viruses were preincubated with MAbs but not when cells were preincubated with MAbs before inoculation, and the MAbs were shown to precipitate 125I-labeled gp120. The MAbs therefore define carbohydrate structures expressed by the viral envelope glycoprotein gp120, indicating that glycans of the viral envelope are possible targets for immunotherapy or vaccine development or both.

M3 - Journal article

VL - 64

SP - 2833

EP - 2840

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 6

ER -

ID: 34125781